S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
SLNCF · Silence Therapeutics Plc Ordinary shares (United Kingdom)
OTC MARKETS - Real Time Price • USD
$6.37
+0.10
(+1.68%)
● Overnight
DAY'S RANGE
$6.37
$6.37
$6.38
52-WEEK RANGE
$6.37
$1.06
$6.38
What's happening
- SLNCF is up 1.68% today, trading at $6.37. — Live quote
- It's trading within 3% of its 52-week high ($6.38). (Finnhub fundamentals)
- Reports earnings on 2026-11-05, 14 days away. (Finnhub earnings calendar)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
SLNCF
+218.50%
vs S&P 500
+217.02%
1-YEAR RETURN
SLNCF
-72.00%
vs S&P 500
-75.27%
6-MONTH RETURN
SLNCF
-31.07%
3-MONTH RETURN
SLNCF
+7.05%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.26
Est. $—
2025-01-26 (Q4 2024)
$0.21
Est. $—
2024-01-26 (Q4 2023)
$-0.37
Est. $—
Valuation Measures & Ratios
Enterprise Value4$1.21B
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)1452.73
Price / Book74.66
EV4 / Revenue2895.84
EV4 / EBITDA—
Profit Margin-8943.86%
Operating Margin-9345.05%
Return on Equity (ROE8)-103.26%
Return on Assets (ROA9)-56.37%
Avg Volume (3M)1,530
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short2,350
Change from Prior Settlement+0.00%
% of Float—
Days to Cover (Short Ratio)130.56
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 305.3% on the provider's reported measure. Finnhub fundamentals ↗
- Latest SEC filing is Form 8-K, filed 2026-10-19; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -8943.9%. Finnhub fundamentals ↗
- Trailing 52-week price return is -72.0%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on SLNCF
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $422.0K | $159.0K | $224.0K | $142.0K | $1.5M | $756.0K | $15.7M |
| Gross profit | $0 | $411.0K | $95.0K | $139.0K | $88.0K | -$2.1M | -$2.6M | $12.9M |
| Operating income | -$13.9M | -$15.7M | -$26.2M | -$24.0M | -$28.4M | -$30.0M | -$23.4M | -$5.6M |
| Net income | -$12.3M | -$15.0M | -$21.0M | -$27.4M | -$28.5M | -$35.5M | -$19.8M | -$2.3M |
| EPS (diluted) | $-0.09 | $-0.11 | $-0.15 | $-0.19 | $-0.20 | $-0.25 | $-0.14 | $-0.02 |
| EPS (basic) | $-0.09 | $-0.11 | $-0.15 | $-0.19 | $-0.20 | $-0.25 | $-0.14 | $-0.02 |
| Operating margin | — | -$3.7K | -$16.5K | -$10.7K | -$20.0K | -$2.0K | -$3.1K | -$36 |
| Net margin | — | -$3.5K | -$13.2K | -$12.2K | -$20.1K | -$2.4K | -$2.6K | -$15 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $106.4M | $115.1M | $131.4M | $146.8M | $165.2M | $185.3M | $202.6M | — |
| Total liabilities | $67.9M | $65.7M | $69.1M | $72.7M | $71.1M | $72.6M | $68.6M | — |
| Stockholders' equity | $38.5M | $49.4M | $62.3M | $74.1M | $94.2M | $112.7M | $134.0M | $126.7M |
| Total current assets | $94.3M | $102.9M | $118.7M | $133.6M | $148.6M | $169.8M | $187.4M | — |
| Total current liabilities | $12.7M | $10.5M | $13.6M | $17.4M | $14.8M | $19.3M | $16.8M | — |
| Cash & equivalents | $72.1M | $5.7M | $11.3M | $82.0M | $41.7M | $64.9M | $121.3M | — |
| Marketable securities (current) | $0 | $64.4M | $73.8M | $20.2M | $72.4M | $71.6M | $26.0M | — |
| Accounts receivable | — | $0 | $0 | $28.0K | $85.0K | $41.0K | $972.0K | — |
| Other current assets | $12.9M | $10.6M | $11.5M | $9.3M | $14.4M | $16.4M | $14.7M | — |
| Property, plant & equipment | $1.3M | $1.4M | $1.6M | $1.7M | $1.8M | $1.7M | $1.8M | — |
| Goodwill | $10.3M | $10.4M | $10.6M | $10.6M | $10.6M | $10.6M | $9.4M | $9.4M |
| Intangible assets | — | — | $288.0K | — | — | — | $312.0K | — |
| Other non-current assets | $127.0K | $127.0K | $127.0K | $399.0K | $3.9M | $3.6M | $3.6M | — |
| Deferred revenue (current) | $0 | $0 | $168.0K | $301.0K | $457.0K | $392.0K | $306.0K | — |
| Common stock & paid-in capital | $10.3M | $10.3M | $10.3M | $10.3M | $10.3M | $10.3M | $10.3M | — |
| Retained earnings | -$589.6M | -$577.5M | -$562.6M | -$550.8M | -$529.8M | -$502.5M | -$474.0M | — |
| Accumulated other comprehensive income (loss) | -$3.3M | -$3.4M | -$3.0M | -$3.1M | -$1.4M | -$8.1M | -$11.8M | — |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.5M | -$15.6M | -$17.3M | -$10.9M | -$21.8M | -$12.3M | -$27.5M | -$25.6M |
| Investing cash flow | $64.9M | $10.0M | -$53.3M | $51.3M | -$1.6M | -$44.4M | $66.1M | -$38.1M |
| Financing cash flow | $2.0K | $0 | $0 | $0 | $1.0K | $14.0K | -$98.0K | $8.0M |
| Free cash flow | $1.5M | -$15.6M | -$17.3M | -$10.9M | -$21.8M | -$12.3M | -$27.5M | -$25.7M |
| Capital expenditures | $0 | $0 | $0 | $3.0K | $48.0K | $4.0K | $62.0K | $64.0K |
| Share-based compensation | $1.3M | $2.4M | -$86.0K | $2.5M | $2.1M | $3.5M | $4.0M | $4.1M |
| Deferred income taxes | $1.0K | — | $0 | $1.0K | $10.0K | $0 | $324.0K | $49.0K |
| Change in accounts receivable | $0 | $0 | -$30.0K | -$62.0K | $8.0K | -$940.0K | $611.0K | -$1.8M |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 |
|---|---|---|---|---|
| Revenue | $559.0K | $43.3M | $31.6M | $21.7M |
| Gross profit | $344.0K | $31.4M | $18.8M | $8.2M |
| Operating income | -$91.1M | -$63.3M | -$64.4M | -$61.0M |
| Net income | -$88.6M | -$45.3M | -$54.2M | -$50.3M |
| EPS (diluted) | $-0.63 | $-0.33 | $-0.49 | $-0.52 |
| EPS (basic) | $-0.63 | $-0.33 | $-0.49 | $-0.52 |
| Operating margin | -$16.3K | -$146 | -$203 | -$282 |
| Net margin | -$15.9K | -$105 | -$171 | -$232 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $131.4M | $202.6M | $119.4M | — | — |
| Total liabilities | $69.1M | $68.6M | $97.5M | — | — |
| Stockholders' equity | $62.3M | $134.0M | $22.0M | $27.2M | $12.4M |
| Total current assets | $118.7M | $187.4M | $103.2M | — | — |
| Total current liabilities | $13.6M | $16.8M | $22.3M | — | — |
| Cash & equivalents | $11.3M | $121.3M | $68.8M | — | — |
| Marketable securities (current) | $73.8M | $26.0M | — | — | — |
| Accounts receivable | $0 | $972.0K | $290.0K | — | — |
| Other current assets | $11.5M | $14.7M | $11.6M | — | — |
| Property, plant & equipment | $1.6M | $1.8M | $1.9M | — | — |
| Goodwill | $10.6M | $9.4M | $10.0M | $9.7M | — |
| Intangible assets | $288.0K | $312.0K | — | — | — |
| Other non-current assets | $127.0K | $3.6M | $3.6M | — | — |
| Deferred revenue (current) | $168.0K | $306.0K | $6.6M | — | — |
| Common stock & paid-in capital | $10.3M | $10.3M | $8.8M | $8.2M | — |
| Retained earnings | -$562.6M | -$474.0M | -$431.9M | — | — |
| Accumulated other comprehensive income (loss) | -$3.0M | -$11.8M | -$10.7M | — | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 |
|---|---|---|---|---|
| Operating cash flow | -$62.3M | -$67.6M | -$49.5M | -$57.0M |
| Investing cash flow | -$48.0M | -$22.0M | $19.3M | -$20.5M |
| Financing cash flow | $15.0K | $142.1M | $31.9M | $52.6M |
| Free cash flow | -$62.3M | -$67.9M | -$49.5M | -$57.2M |
| Capital expenditures | $55.0K | $211.0K | $56.0K | $173.0K |
| Share-based compensation | $8.1M | $16.3M | $16.3M | $12.7M |
| Deferred income taxes | $11.0K | $845.0K | $956.0K | $688.0K |
| Change in accounts receivable | -$1.0M | $904.0K | -$392.0K | $723.0K |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding SLNCF as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Insider activity is not available for this symbol right now.
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 05:15 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-19 | 8-K | 2026-10-18 | View on SEC.gov → |
| 2026-08-13 | 4 | 2026-08-10 | View on SEC.gov → |
| 2026-08-12 | 8-K | 2026-08-10 | View on SEC.gov → |
| 2026-08-10 | 8-K | 2026-08-10 | View on SEC.gov → |
| 2026-08-10 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-10 | 8-K | 2026-08-10 | View on SEC.gov → |
| 2026-07-07 | 4 | 2026-06-29 | View on SEC.gov → |
| 2026-06-23 | 8-K | 2026-06-23 | View on SEC.gov → |
| 2026-06-16 | 8-K | 2026-06-16 | View on SEC.gov → |
| 2026-06-11 | 8-K | 2026-06-11 | View on SEC.gov → |
| 2026-05-18 | 8-K | 2026-05-18 | View on SEC.gov → |
| 2026-05-07 | 10-Q | 2026-03-31 | View on SEC.gov → |
Recent news
Headlines about SLNCF (Silence Therapeutics Plc Ordinary shares (United Kingdom)). Links open the publisher — we don’t host full articles.
-
A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday
Yahoo · 2026-10-20 -
Does Silence Therapeutics (SLN) Have the Potential to Rally 82.84% as Wall Street Analysts Expect?
Yahoo · 2026-10-20 -
Is Silence Therapeutics (NasdaqGM:SLN) Reasonable Near Its $20 Deal Price?
Yahoo · 2026-10-20 -
Silence Therapeutics (SLN) Gets 130% Premium Offer From Merck, Shares Surge Over 100%
Yahoo · 2026-10-19 -
Silence Therapeutics: Downgrade To Hold On Merck KGaA Acquisition And PV siRNA
SeekingAlpha · 2026-10-19 -
Merck KgaA Is Paying More Than Double for This Gene-Silencing Biotech, Which Is Soaring 125%
Yahoo · 2026-10-19 -
Silence Therapeutics jumps 59% on Merck takeover
Yahoo · 2026-10-19 -
Silence Therapeutics stock soars 125% on Merck acquisition
Yahoo · 2026-10-19
No headlines in this category right now — try “All”.